Herpesvirus-based gene therapy vectors offer an attractive alternative to retroviral vectors because of their episomal nature and ability to accommodate large transgenes. Saimiriine herpesvirus 2 (HVS) is a prototypical gamma-2 herpesvirus that can latently infect numerous different cell types. A cosmid-generated HVS vector in which transforming genes have been deleted and the marker gene encoding enhanced green fluorescent protein (HVS-GFP) has been incorporated was evaluated for its potential to transduce CD34+ haemopoietic progenitors selected from cord blood.
Introduction
In principle, herpesvirus vectors have a number of advantages for gene therapy. They can package large DNA insertions and infect nondividing cells. 1, 2 One member of this family is Saimiriine herpesvirus 2 (HVS), a gamma-2 herpesvirus of the squirrel monkey, which persists in lymphocytes of its natural host without causing any obvious disease. 3 Another useful property of HVS is that it persists as an episome, allowing sustained expression of a transgene in target cells without integration into the host cell genome. [4] [5] [6] [7] Using a disabled mutant of HVS (in which the transforming genes had been eliminated completely), high-efficiency infection was achieved in a broad range of human cell lines, murine embryonic stem cells (ES) and tumour xenografts. [4] [5] [6] [7] [8] Although efficient transduction of primary bone marrow stromal cells by HVS has been reported, successful transduction of primary human haemopoietic cells by HVS has not previously been described. 9 CD34+ cells completely reconstitute haemopoiesis when transplanted in either mice or human recipients. [10] [11] [12] Thus, the CD34+ population is an ideal target for gene therapy as it contains both stem and progenitor cells. Among the CD34+ population are the myeloid progenitor cells, which can be identified in standard clonogenic colony-forming cell (CFC) assays. 13 In these assays, the progenitor cells are immobilized in a soft-gel matrix supplemented with growth factors and form colonies of granulocytes, megakaryocytes, macrophages or erythroid cells, either alone or mixed with other myeloid lineages. The CD34+ cells may also be stimulated in liquid culture with specific growth factors and/ or cytokines to generate a variety of haemopoietic cells of the myeloid lineages. [14] [15] [16] We have used both systems to investigate whether HVS-GFP could transduce CD34+ progenitor cells and allow expression of the marker gene in the differentiated cells. We were also interested to establish whether efficient vector transduction could be achieved in cord blood cells.
The HVS-GFP vector has been described in detail elsewhere. 9 Briefly, HVS-GFP was constructed from the HVS strain C488 genome using a cosmid-based approach. The HVS-based vector contains enhanced green fluorescent protein (GFP) under the control of the cytomegalovirus (CMV) promoter. HVS-GFP was propagated in permissive owl monkey kidney cells (OMK-637). Tissue culture supernatants derived from infected OMK cultures were cleared of cellular debris and concentrated stock of the virus was obtained by high-speed centrifugation. Virus titre of this working stock was determined by limiting dilution assays on OMK monolayers.
CD34+ cells were isolated from human umbilical cord blood by positive selection with immunomagnetic beads, resulting in preparations that were greater than 80% pure as determined by flow cytometry analysis. 16 We used transduction conditions as described previously for a range of haemopoietic cell lines. 17 Typically, 1 Â 10 5 immunoselected CD34+ cells were incubated with HVS-GFP at a cell density of 1 Â 10 6 /ml. The cells and virus were incubated for a period of 1 h at 371C in a humidified atmosphere. After this time, unbound virus was removed by extensive washing in phosphatebuffered saline (PBS). Mock transduction consisted of incubating cells with a volume of PBS equal to that which contained HVS-GFP in the transduced cultures, followed by identical further manipulation. Initially, we performed both a kinetic and dose-effect analysis to determine the amount of GFP expression that could be obtained. GFP expression was determined by flow cytometry on sequential days after incubation with increasing MOI (multiplicity of infection) of HVS. Table  1 shows the percentage of GFP+ cells with fluorescence above that of mock-transduced controls. We observed a dose-dependent increase in green fluorescence from transduced CD34+ cells, suggesting that the amount of GFP expression correlates with the amount of input virus. Approximately 60% transduction efficiency is achieved with a single 1 h exposure of CD34+ cells to the HVS vector at an MOI of 27. Using this dose of virus, we observed minimal loss of the percentage of GFPexpressing cells, indicating maintenance of the vector within the population. Furthermore, extended incubation times of up to 2 h did not improve significantly the percentage of transduced cells. To assess the extent of gene transfer into CD34+ progenitor cells, equal numbers of transduced and mock-transduced cells were plated in the CFU-GEMM assay immediately after transduction. As shown in Table 2 , in four separate experiments using different cord blood samples, both transduced and control cells gave rise to similar numbers of colonies consisting of granulocyte/macrophage, macrophage or erythroid colonies. A total of 1092 colonies were examined from the four experiments. In addition, different viral stock preparations were used indicating the reproducibility of this vector. When the assays were assessed at 14 days, the colonies containing GFP+ cells were predominantly erythroid colonies (Table 2, Figure  1 ). The proportion of GFP+ erythroid colonies was variable, ranging from 39.3 to 81.2% in five experiments. Among the granulocyte/macrophage colonies, less than 5% were GFP+ at this time point. Control cultures showed no fluorescent colonies when imaged under the same conditions and exposure time, demonstrating that the fluorescent images do not represent an artefact of autofluorescence. Figure 1 illustrates examples of transduced (GFP+) and mock-transduced (no GFP) erythroid colonies. This is the first demonstration that the HVS-GFP vector infects primitive human haemopoietic progenitor cells. Even after 28 days, fluorescent colonies were still clearly visible on the tissue culture plates (data not shown).
To confirm GFP expression and cellular phenotype, cell suspensions derived from the colonies were stained with a marker specific to the erythroid lineage, Glycophorin A (CD235a) and analysed by flow cytometry. The dotplots from a representative experiment are illustrated in Figure 2 . In both the control and HVS-treated cultures, more than 90% of the cells express Glycophorin A. In the HVS-transduced cultures, the majority of the cell population expressing Glycophorin A also coexpresses GFP ( Figure 2d ).
Next, we evaluated the effect of the virus on erythroid differentiation in liquid cultures. The CD34+ cells obtained by immunomagnetic selection were transduced with HVS-GFP and cultured for 14 days in stem cell factor, (SCF) thrombopoietin (TPO) and erythropoietin (EPO) as described previously. 16 Mock-transduced CD34+ cells cultured in the same cytokine combination were used as controls. Similar to the results described in Figures 1 and 2 , CD34+ cord blood cells transduced with HVS gave rise to GFP-expressing erythroid cells after expansion and differentiation in liquid culture (data not shown). However, there was some variation between the cultures. In the mock-transduced cultures, the cells expanded 200-to 320-fold with a gradual increase in the clonogenic cell content. Over the same time period, expansion of HVS-transduced cell numbers increased by a factor of 420-to 680-fold after 14 days. The difference in growth kinetics between the mock-transduced and transduced cells could be due to either CFU-GEMM assay was performed in methylcellulose medium (H4330; StemCell Technologies) supplemented with 50 ng/ml human SCF, 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF), 10 ng/ml interleukin-3 (IL-3; R&D Systems) and 2.5 U/ml human EPO (Boehringer). Cells (2 Â 10 3 ) were mixed in the methylcellulose medium and plated in triplicate on 24-well plates. The cultures were incubated at 371C in a humidified atmosphere of 5% CO 2 for 14 days before scoring for erythroid and granulocyte/macrophage colonies. ÀHVS indicates cultures that were mock transduced, whereas +HVS indicates those that have been transduced with the HVS-GFP vector. A total of 1 Â 10 5 CD34+ cells were incubated with the appropriate volume of virus suspension for 60 min at 371C. After washing, the transduced cells were resuspended in medium (Stemspan; Stem Cell Technologies) containing 300 ng/ml SCF, 100 ng/ml fms-like tyrosine kinase ligand (Flt-3 ligand) and 100 ng/ml TPO (R&D Systems). Cultures were incubated at 371C in a humidified atmosphere of 5% CO 2 . At 24, 48 and 120 h, GFP expression was analysed by flow cytometry using a FACSVantage system (Becton Dickinson). ND ¼ not determined.
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GM Doody et al transformation or activation of the cells by the virus.
There was a decline in the total numerical content of progenitors transduced with HVS by up to 30%, suggesting that these progenitors were differentiating more rapidly in liquid culture. Morphological examination revealed that there was no difference in the type of cells generated in the transduced and mock-transduced cultures by day 14. Under this optimized protocol for erythroid expansion, transduction and GFP expression did not apparently alter the potential of human cord blood CD34+ cells to differentiate into erythroid cells. As the progenitors differentiated normally, this suggests activation due to viral transduction rather than transformation. The HVS orf73 gene product is the structural and positional homologue of Kaposi's sarcoma-associated virus (KSHV) LANA, and has been shown to suppress HVS transduction of human haemopoietic progenitors GM Doody et al lytic replication and to assure maintenance of the viral episome by tethering the virus genome to the host chromosome. 18, 19 To establish whether the differentiated HVS-transduced CD34+ progenitor cells exhibited multicopy episomal maintenance, fluorescence in situ hybridization (FISH) was performed on metaphase chromosomes. Using a probe to detect the HVS genome, we observed a random punctate pattern consistent with the association of greater than 50 HVS episomes with the host chromosomes in a given nucleus (Figure 3a) . The pattern was indistinguishable from that seen in HVStransduced Jurkat T cells, which are known to support latent infection, and that reported previously for both HVS and KSHV. 17, 19, 20 Additionally, we estimated that 40% of the HVS-transduced cells gave a positive signal with the FISH probe, which is in good agreement with the GFP expression data. Although the HVS vector used in our studies has had the genes responsible for transformation removed, it remains replication competent. Therefore, we evaluated the expression of the latency-associated orf73 gene or a lytically expressed gene that encodes the viral envelope protein, glycoprotein B (orf8). 21 RT-PCR was performed on cDNA samples derived from HVS-transduced cells or their mocktransduced counterparts grown in a CFU-GEMM assay or using the liquid erythroid differentiation conditions. The results shown in Figure 3b demonstrate expression of the orf73 gene in HVS-transduced cultures. However, a small amount of the lytic gene product orf8 was also detected in these samples. Gardella gel analysis of mockor HVS-transduced erythroid expansion cultures confirmed the simultaneous observation of both episomal and linear viral DNA (Figure 3c ). The presence of the orf8 gene product and linear viral genome is indicative of lytic replication. A plaque formation assay on OMK monolayers using tissue culture supernatant from HVStransduced erythroid expansion cultures failed to provide evidence for infectious virus (data not shown). This assay may have been of insufficient sensitivity to detect low levels of virus production, alternatively, the observed viral replication may be abortive. Furthermore, our differentiation cultures contain a mixture of cells at various stages of erythroid maturation, whereas most previous studies have evaluated HVS persistence in homogeneous cell populations. It is conceivable that a particular stage of development within the heterogeneous group of differentiating cells is associated with the production of virus. A previous report demonstrated HVS transduction of human haemopoietic progenitors GM Doody et al viral replication after infection of a number of cell types with a nonselectable HVS vector and highlighted the need for a replication-disabled mutant in the development of a gene therapy vector. 5 Our results support those conclusions.
Improved viral vectors are still required for gene therapy applications. Currently, retroviral vectors are the vehicles of choice as they can provide long-term gene expression by stable integration into the host genome. However, this random integration can also result in insertional mutagenesis. 22 In contrast, HVS offers the potential advantage that it may establish lifelong latent infections where the genomic material exists as a stable episome. Although some primates have been reported to succumb to a lymphoproliferative disease after HVS infection, this could be eliminated completely by deletion of two particular transforming genes. 8 To date, there is no evidence that HVS integrates into the host genome. Further in vivo studies are needed to show sustained expression and we are now examining the effect of long-term transgene expression in NOD/SCID mice using the HVS-GFP vector.
A previous report from this laboratory indicated low levels of transduction among primary CD34+ cells using vectors based on HVS strain A11 with enhanced GFP under the control of the CMV promoter and the neomycin resistance (neo r ) marker genes. 16 In the present study, we made some modifications. First, HVS-GFP, a recombinant vector constructed from the HVS strain C488 was selected for studies with primary human haemopoietic cells, as human bone marrow stromal cells were transduced with over 90% efficiency using this vector. 8, 17 Further, the clonogenic assays were optimized by using recombinant human growth factors, which are more efficient for colony formation than conditioned medium. Lastly, our vector does not contain a drugselectable marker, and thus CFU-GEMM assays were not performed in the presence of high concentrations of drugs such as geneticin. Under these conditions, the cloning efficiency and detection of transduced progenitor cells is improved significantly. An alternative explanation is that the gene marking of the cells was more efficient. Transduced cells proliferated normally in colony assays to generate up to 81% of erythroid colonies expressing the marker gene. In the liquid cultures, GFPexpressing erythroid cells were identified with mature characteristics expressing a specific marker of the erythroid lineage. The low GFP expression in granulocyte/macrophage colonies suggests that the viral construct may be expressed at lower levels in nonerythroid lineages.
In conclusion, the work described herein provides evidence that an HVS vector is capable of transducing early human haematopoietic progenitors and is subsequently maintained as the cells both proliferate and differentiate. These results should facilitate the use of the HVS vector for genetic manipulation of haemopoietic cells in erythroid disorders.
